GLP-1R/GCGR co-agonists may hold advantages over GLP-1R mono-agonists for treating obesity and related metabolic diseases as their GCGR-mediated effects on energy expenditure can promote additional weight loss [35,60,61]. The gene discussed is GCGR; the disease is obesity due to melanocortin 4 receptor deficiency.